Vanda’s Tasimelteon Gets Panel OK: “A Well-told Story That’s Plausible”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee supports using secondary endpoints to establish clinical benefit of treatment for non-24 sleep-wake disorder.